Femasys (FEMY)
(Delayed Data from NSDQ)
$1.27 USD
-0.06 (-4.51%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.27 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FEMY 1.27 -0.06(-4.51%)
Will FEMY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for FEMY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FEMY
Femasys (FEMY) to Report Q3 Earnings: What's in the Cards?
Bears are Losing Control Over Femasys Inc. (FEMY), Here's Why It's a 'Buy' Now
FEMY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Femasys Inc. (FEMY) Reports Q3 Loss, Lags Revenue Estimates
Voyager Therapeutics (VYGR) Beats Q3 Earnings and Revenue Estimates
Femasys Inc. (FEMY) Reports Q2 Loss, Tops Revenue Estimates
Other News for FEMY
Femasys Releases Updated Investor Presentation Information
Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives
Femasys CEO meets with members of Congress to raise awareness
Femasys: A Buy Rating on Innovative Reproductive Solutions and Market Expansion Potential
Femasys price target raised by $2 at H.C. Wainwright, here's why